Search Results

You are looking at 131 - 140 of 2,911 items for :

  • Refine by Access: All x
Clear All
Full access

HSR19-076: A Prospective Study of the Usage of Pain Medication, Cost, Alternative Medication Use, and Outcome by Cancer Patients in Real World

Praveen Adusumilli, Vidya Viswanath, and Raghunadha Rao Digumarthi

Introduction: Perception of pain and the need to treat it is highly variable, even amongst oncologists. Availability of pain specialists is an added advantage. This is an analysis of prescription patterns of pain medication and its outcome in

Full access

Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment

Full access

Issues of Imatinib and Pregnancy Outcome

Jane Apperley

to have functions that may be important in gonadal development, implantation, and fetal development. 1 - 5 An international registry of pregnancy outcome was recently established by Novartis to compile pregnancy outcomes in women who have been

Full access

Predictors of Outcome in Bladder Cancer

John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick

) remains low, and selecting the subset of patients most likely to benefit from NAC has proven difficult. Patients with organ-confined MIBC have experienced excellent oncologic outcomes absent the use of NAC (5-year disease-specific survival of ≈80%). 12

Full access

SupportScreen: A Model for Improving Patient Outcomes

Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge, and Daniel Smith

authors have taken this process a step further by automating biopsychosocial screening through the use of touch-screen technology. 12 SupportScreen Improved Patient Outcomes “At Your Fingertips” The authors' team developed a new touch screen

Full access

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit

Full access

Patient-Reported Outcomes in Multiple Myeloma

Stephanie J. Lee

multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 . 6 American Society of Clinical Oncology . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 7

Full access

A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman

associated with poor outcome among patients with glioblastoma. 30 , 31 VEGF-A isoforms generated by alternative splicing can also originate from host sources, such as invading macrophages and platelets, whereas tumor stroma can sequester larger isoforms that

Full access

Management of Patients With Lung Cancer and Poor Performance Status

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

patient populations that respond differently to treatment and have different outcomes. 7 Another challenge in interpreting the trial evidence for this group of patients is the subjectivity associated with assigning a PS to any given patient. A recent

Full access

New Treatment Guidelines for Penile Cancer

Philippe E. Spiess

NCCN Panel on bladder and penile cancers. With the use of non–evidence-based treatment approaches, outcomes can widely vary. To clarify some of the controversies associated with the treatment of penile cancer, NCCN has created inaugural NCCN Clinical